Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: COR (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $387.93
1 Year Target Price $387.93
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.51% | Avg. Invested days 67 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 66.16B USD | Price to earnings Ratio 42.9 | 1Y Target Price 387.93 |
Price to earnings Ratio 42.9 | 1Y Target Price 387.93 | ||
Volume (30-day avg) 17 | Beta 0.63 | 52 Weeks Range 222.21 - 377.54 | Updated Date 12/28/2025 |
52 Weeks Range 222.21 - 377.54 | Updated Date 12/28/2025 | ||
Dividends yield (FY) 0.65% | Basic EPS (TTM) 7.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.48% | Operating Margin (TTM) 1.14% |
Management Effectiveness
Return on Assets (TTM) 3.26% | Return on Equity (TTM) 123.75% |
Valuation
Trailing PE 42.9 | Forward PE 19.34 | Enterprise Value 69466099076 | Price to Sales(TTM) 0.21 |
Enterprise Value 69466099076 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.22 | Enterprise Value to EBITDA 18.54 | Shares Outstanding 193993444 | Shares Floating 185649786 |
Shares Outstanding 193993444 | Shares Floating 185649786 | ||
Percent Insiders 4.22 | Percent Institutions 96.71 |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly AmerisourceBergen Corporation, was founded in 2001 through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. The company is a global pharmaceutical sourcing and specialty services company. Significant milestones include its consistent growth through strategic acquisitions and expansion into international markets, rebranded to Cencora in August 2023 to reflect its broader global reach and diversified offerings beyond traditional wholesale distribution.
Core Business Areas
- Pharmaceutical Distribution: Cencora is one of the largest distributors of pharmaceutical products and healthcare services in the United States. This segment involves the sourcing, warehousing, and distribution of pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies to pharmacies, hospitals, and other healthcare providers.
- Specialty Services: This segment provides a range of services to support pharmaceutical manufacturers, including market access, patient support programs, specialty pharmacy services, and commercialization solutions for complex and specialty drugs.
- Manufacturer Services: Cencora offers a suite of services to pharmaceutical manufacturers, including data analytics, supply chain management, and logistics support to help them bring products to market and manage their commercial operations effectively.
Leadership and Structure
Cencora Inc. is led by a seasoned executive team with extensive experience in the healthcare and pharmaceutical industries. The organizational structure is designed to support its global operations and diverse business segments, with dedicated leadership for distribution, specialty services, and manufacturer solutions. The Board of Directors oversees the company's strategic direction and governance.
Top Products and Market Share
Key Offerings
- Pharmaceutical Distribution Services: Core offering includes the reliable and efficient distribution of a wide range of pharmaceutical products to over 45,000 customer locations. Market share in this segment is significant, placing Cencora among the top players in the US pharmaceutical wholesale market. Key competitors include McKesson Corporation (MCK) and Cardinal Health (CAH). The revenue generated from this segment constitutes a substantial portion of Cencora's overall revenue.
- Specialty Pharmaceutical Services: Services include logistics, patient support programs, and specialty pharmacy network management for high-cost and complex medications. This segment is growing in importance, catering to the increasing demand for specialized treatments. Competitors include closely held specialty pharmacy providers and divisions of larger healthcare companies. Revenue from this area is expanding as biopharmaceutical innovation continues.
- Data Analytics and Technology Solutions: Provides insights and operational support to manufacturers and providers, leveraging advanced data analytics for supply chain optimization and market understanding. Competitors include specialized healthcare analytics firms and technology providers. While not directly product-based, these services are critical enablers for their core offerings.
Market Dynamics
Industry Overview
The pharmaceutical distribution and services industry is characterized by consolidation, increasing regulatory scrutiny, and a growing demand for specialized services. Key trends include the rise of specialty drugs, the expansion of biosimilars, and the focus on value-based care. The industry plays a critical role in the healthcare ecosystem, ensuring timely access to medications.
Positioning
Cencora holds a strong position as a leading global provider of pharmaceutical sourcing and specialty services. Its competitive advantages include its extensive distribution network, robust relationships with manufacturers and healthcare providers, and its ability to offer integrated solutions across the pharmaceutical value chain. The company's scale provides significant purchasing power and operational efficiencies.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical distribution and related services is in the hundreds of billions of dollars globally, driven by global healthcare spending and pharmaceutical sales. Cencora is positioned to capture a significant portion of this market through its broad service offerings and global presence, especially in North America and increasingly in Europe and other international regions.
Upturn SWOT Analysis
Strengths
- Extensive global distribution network and logistics capabilities.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Diversified revenue streams from distribution and specialty services.
- Significant scale and purchasing power.
- Experience in managing complex supply chains and specialty pharmaceuticals.
Weaknesses
- Reliance on a few large pharmaceutical manufacturers for a significant portion of revenue.
- Potential exposure to regulatory changes and pricing pressures.
- Integration risks associated with past and future acquisitions.
- Complex operational structure across multiple segments and geographies.
Opportunities
- Growth in the specialty and biologics drug market.
- Expansion into emerging markets and international geographies.
- Leveraging data analytics to enhance services and client value.
- Strategic partnerships and acquisitions to broaden service offerings.
- Increased demand for patient support and adherence programs.
Threats
- Increased competition from other distributors and emerging players.
- Government price controls and reimbursement changes.
- Supply chain disruptions due to geopolitical events or pandemics.
- Cybersecurity risks and data breaches.
- Shifting healthcare policies and payer negotiations.
Competitors and Market Share
Key Competitors
- McKesson Corporation (MCK)
- Cardinal Health (CAH)
- UnitedHealth Group (UNH) - Optum Rx division
- CVS Health (CVS) - CVS Caremark division
Competitive Landscape
Cencora's advantages lie in its comprehensive service offerings, deep industry expertise, and strong customer relationships. However, it faces intense competition from established players with similar scale and broad capabilities. The market is highly competitive, with companies vying for market share through pricing, service innovation, and strategic partnerships.
Major Acquisitions
PharMerica Corporation
- Year: 2023
- Acquisition Price (USD millions): 2600
- Strategic Rationale: Acquired to expand its presence in the institutional pharmacy market, offering integrated pharmacy services to long-term care facilities and other institutional clients, enhancing its specialty services portfolio.
Specialty Networks
- Year: 2022
- Acquisition Price (USD millions): Undisclosed
- Strategic Rationale: Acquisitions of various specialty network providers to bolster its capabilities in managing patient access and support programs for complex and high-cost medications.
Growth Trajectory and Initiatives
Historical Growth: Cencora has experienced consistent historical growth, fueled by organic expansion and strategic acquisitions that have broadened its service portfolio and geographical reach. The company has successfully navigated industry consolidation and evolving healthcare landscapes.
Future Projections: Future growth projections for Cencora are generally positive, driven by the expanding market for specialty pharmaceuticals, increased outsourcing by manufacturers, and its ongoing international expansion. Analyst estimates often point to continued revenue and earnings growth, supported by strategic initiatives and market trends.
Recent Initiatives: Recent initiatives include the rebranding to Cencora to emphasize its global identity, strategic investments in technology and data analytics, and continued focus on expanding its specialty services and international presence. The company also actively pursues bolt-on acquisitions to enhance its capabilities and market position.
Summary
Cencora Inc. is a robust pharmaceutical distributor and services provider with a strong market position and global reach. Its diversified business model and strategic focus on specialty pharmaceuticals are driving growth. The company's strengths lie in its extensive network and strong relationships, though it faces significant competition and regulatory challenges. Continued investment in innovation and international expansion are key to its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Financial News Outlets (e.g., Wall Street Journal, Bloomberg)
- Industry Research Reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market share data and financial figures are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 47000 | Website https://www.cencora.com |
Full time employees 47000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.